After lenalidomide/bortezomib-based induction therapy the monocyte-1 and all CD163+ monocyte populations (monocytes 3 and 4) increased, and total NK cells decreased in patients with MM (p < 0.05) (supplemental Fig. 8). This evidence concerns the gene CD163 and Miyoshi myopathy.